<DOC>
	<DOCNO>NCT00463320</DOCNO>
	<brief_summary>This two-part study evaluate safety , tolerability pharmacokinetics single ( Part A ) repeat ( Part B ) eye drop dose pazopanib healthy adult elderly subject .</brief_summary>
	<brief_title>A Study To Evaluate The Safety , Tolerability And Pk Of Pazopanib Eye Drops In Healthy Adult And Elderly Subjects .</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Tetrahydrozoline</mesh_term>
	<criteria>Agerelated macular degeneration patient diagnose subfoveal choroidal neovascularization study eye , follow characteristic require : central subfield thickness &gt; 300 micron investigatordetermined OCT ( inclusive subretinal fluid ) ; active subfoveal leakage determine investigatordetermined fluorescein angiography ; minimally classic occult classic D8 lesion ; lesion size great 12 disc area ; CNV &gt; 50 % lesion area ; &lt; 50 % lesion area blood ; â‰¤ 25 % lesion area fibrosis . Male female 50 year age . Bestcorrected ETDRS visual acuity study eye 80 24 letter inclusive ( approximately 20/25 20/320 4/5 4/63 ) screening . A female subject eligible participate nonchildbearing potential define either premenopausal document tubal ligation hysterectomy , postmenopausal define 12 month spontaneous amenorrhea . In questionable case postmenopausal status blood sample simultaneous follicle stimulate hormone ( FSH ) &gt; 40 MlU/ml estradiol &lt; 40 pg/ml ( &lt; 140 pmol/L ) confirmatory . Subject willing able return study visit , willing able comply protocol requirement procedure . Subject capable give write informed consent , include compliance requirement restriction list consent form . If subject unable read consent form due visual impairment consent must read subject verbatim person administer consent , family member legally acceptable representative . If subject unable provide write informed consent due visual impairment , write informed consent behalf subject must provide legally acceptable representative . ( Note : Consent legally acceptable representative allow accordance local law , regulation ethic committee policy . ) Exclusion criterion : Additional eye disease study eye could compromise best correct visual acuity ( i.e . glaucoma document visual field loss , clinically significant diabetic retinopathy , ischemic optic neuropathy , retinitis pigmentosa ) . CNV study eye due cause unrelated agerelated macular degeneration . The presence retinal angiomatous proliferation ( RAP ) study eye , determine investigator ( confirmation indocyanine green angiography require ) . Geographic atrophy involve center fovea study eye . Anterior segment vitreous abnormality study eye would preclude adequate observation fundus photograph , fluorescein angiography OCT. Vitreous , subretinal retinal hemorrhage study eye unrelated AMD . More one prior photodynamic therapy ( PDT ) treatment study eye . PDT treatment study eye &lt; 12 week prior dose . Previous treatment study eye ranibizumab ( Lucentis ) bevacizumab ( Avastin ) without resolution exudation ( intraretinal subretinal fluid document OCT ) . Use treatment , either approve experimental , AMD study eye within 60 day first dose investigational product . Intraocular surgery study eye within 3 month dose . Aphakia total absence posterior capsule ( Yttrium aluminum garnet ( YAG ) capsulotomy permit ) study eye . History vitrectomy study eye . Use topical ocular medication study eye within 7 day first dose investigational product expect use topical ocular medication treatment period , exception artificial tear Active treatment fellow eye , exception preservativefree artificial tear . Current use medication know toxic retina , lens optic nerve ( e.g . desferoxamine , chloroquine/hydroxychloroquine , chlorpromazine , phenothiazine , tamoxifen , nicotinic acid , ethambutol ) . Use systemic steroid ( &gt; 10 mg prednisone equivalent/day ) within 14 day first dose . An unwillingness refrain wear contact lenses start screen visit , followup visit Medical history condition : Uncontrolled Diabetes Mellitus , hemoglobin A1c ( HbA1c ) &gt; 10 % . Myocardial infarction stroke within 12 month screen . Active bleeding disorder . Major surgery within 1 month screening . Hepatic impairment . Uncontrolled hypertension , base criterion provide Section 7.2.2 . Note : Initiation adjustment antihypertensive medication permit prior study entry provide referenced criterion meet . ALT AST upper limit normal total bilirubin value 1.5 time upper limit normal screening.. Note : Laboratory test outside normal range may repeat discretion Investigator . A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result . A history know HIV infection . Use prohibit medication list within restrict timeframe relative first dose study medication . History drug alcohol abuse within 6 month study . History sensitivity study medication , component thereof history drug allergy , opinion investigator GSK Medical Monitor , contraindicate participation . A condition situation , opinion investigator , may result significant risk patient , confound study result interfere significantly participation .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>Age-related macular degeneration ( AMD ) ,</keyword>
	<keyword>vascular endothelial growth factor ( VEGF ) receptor ( VEGFR )</keyword>
	<keyword>choroidal neovascularization ,</keyword>
</DOC>